Details of the Drug Combinations

General Information of This Drug (ID: DMG5C8D)

Drug Name

GS-9620 DMG5C8D

Synonyms

GS-9620; 1228585-88-3; Vesatolimod; GS9620; UNII-O8M467C50G; GS 9620; CHEMBL2424780; O8M467C50G; 8-(3-(pyrrolidin-1-ylmethyl)benzyl)-4-amino-2-butoxy-7,8-dihydropteridin-6(5H)-one; 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; 4-Amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one; 4-azanyl-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; Vesatolimod [INN]; Vesatolimod [USAN:INN]; Vesatolimod (USAN/INN); SCHEMBL10083191

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis B virus infection	1E51.0	Phase 2	[1]
Human immunodeficiency virus infection	1C62	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

3 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
GS-9620 + Artesunate	DCUFG0T	Artesunate	HIV-1 Infection	[3]
Rifabutin + GS-9620	DCDMDVS	Rifabutin	Human Immunodeficiency Virus Type 1 (HIV-1) Infection	[4]
Tenofovir disoproxil + GS-9620	DCTYYX4	Tenofovir disoproxil	Chronic Hepatitis B	[5]
------------------------------------------------------------------------------------

References

1	Pharmacokinetic and pharmacodynamic properties of GS-9620, a novel Toll-like receptor 7 agonist, demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. J Pharmacol Exp Ther. 2014 Jan;348(1):96-105.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT03060447) Study to Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated Human Immunodeficiency Virus (HIV-1) Infected Controllers
4	ClinicalTrials.gov (NCT05458102) Drug-Drug Interaction Study of Vesatolimod in Adults With HIV-1 Who Have Very Low or Undetectable Virus Levels
5	ClinicalTrials.gov (NCT02579382) Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated